

Session 2A 2.3 Reengagement and AHD

Tendai Nyagura



Key global statistics for Advanced HIV disease and opportunistic infections

630,000

AIDS-RELATED DEATHS IN 2022

>20-30%

AHD AT BASELINE, SOMETIMES HIGHER (UPTO 50%)

187,000

DEATHS FROM TB AMONG PLHIV IN 2021



DEATHS FROM CRYPTOCOCCAL INFECTION IN 2021

380,000

AIDS-RELATED DEATHS IN THE WHO AFRICAN REGION

1.5M


CHILDREN LIVING WITH HIV


84,000

AIDS-RELATED DEATHS IN CHILDREN WITH HIV **2.1M**

ADULTS LIVING WITH AHD in SSA

Despite scaleup of HIV treatment, large cohort of AHD





Baseline CD4 count	Kenya (SLATE I) (N = 221)			South Africa (SLATE II) (N = 273)			
Median (IQR)	272 (124, 522)			294 (135, 464)			
	Total	0 symptom	≥1 symptoms	Total	0 symptom	≥1 symptoms	
<100 cells/mm ³	21%	6%	14%	18%	4%	14%	
	46	14	32	48	10	38	
\geq 100 and <200 cells/mm ³	16%	10%	7%	18%	8%	11%	
	36	22	14	51	22	29	
≥200 cells/mm ³	63%	43%	20%	64%	41%	23%	
	139	95	44	174	111	63	
Number treatment naïve	206			242			
Median (IQR) if treatment naive	278 (133,525)			291 (136,464)			
Number prior default	15			31			
fian (IQR) if prior default	195 (64, 408)			346 (128, 449)			

38% AHD

(from 55 countries)

IedeA/COHERE collaboration, 2016 Lemme HIV Med 2020 Brennan, JIAS 2019 Huerga, OFID 2021


25% AHD

(Botswana 2015-18) 36-37% AHD (RSA and Kenya)




Estimates of AHD (PHIA surveys)

• Rates higher in men, ages 30-49, and urban residence




AHD by the HIV testing and treatment cascade, by gender





Distribution of AHD by treatment cascade, by country



Disaggregation of all people with AHD	n = 2151	%
Not aware of HIV status	706	32.5
Aware of status but not on ART	216	9.9
On ART but not virally suppressed	543	25.0
Virally suppressed	686	31.6

CD4 count <200 cells/mm³ and not aware of HIV status CD4 count <200 cells/mm³ aware of HIV status but not on ART CD4 count <200 cells/mm³ on ART but not virally suppressed CD4 count <200 cells/mm³ on ART and virally suppressed

https://www.croiconference.org/abstrac t/high-prevalence-of-advanced-hivdisease-in-sub-saharan-africa-ananalysis-of-11-household-surveys/




What about access to CD4?


	% of initiations with CD4 performed	% of initiations with CD4 < 200 cells/mm3
Eswatini		
Kenya		
Malawi		
Uganda	85%	25%



CD4 count and viral load without ART



RIAS Effect of ARVs on CD4 count and viral load



RIAS Impact of treatment interruptions on CD4



SPECIALTIES V TOPICS V MULTIMEDIA V CURRENT ISSUE V LEARNING/CME V AUTHOR CENTER PUBLICATIONS V


ORIGINAL ARTICLE

f 🕺 in

CD4+ Count-Guided Interruption of Antiretroviral

Treatment

Author: The Strategies for Management of Antiretroviral Therapy (SMART) Study Group^{*} Author Info & Affiliations Published November 30, 2006 | N Engl J Med 2006;355:2283-2296 | DOI: 10.1056/NEJMoa062360




The average CD4+ count decreased by 87 cells per cubic millimeter per month during the first 2 months after randomization

After reinitiation of antiretroviral therapy in the drug conservation group, the median time to an HIV RNA level of 400 copies per milliliter or less was **3.1 months**

	Availability of CD4 Cell-Count Data After Reengagement in ART									
Thomadakis C et al. The Effect of HIV Treatment Interruption on	CD4 Da	ita Avai	lable(<i>n</i> = 8,501)	CD4 Data Not Available		Total (<i>n</i> = 10,961)			P Value	
Subsequent Immunological Response. Am J Epidemiol. 2023 Jul 7;192(7):1181-1191.					(<i>n</i> = 2	2,460)				
East Africa data	No.	%	Median (IQR)	No.	%	Median (IQR)	No.	%	Median (IQR)	
Sex										0.883
Female	5,636	66.3		1,627	66.1		7,263	66.3		
Male	2,865	33.7		833	33.9		3,698	33.7		
Age at disengagement from care, years			37.8 (32.0-44.7)			37.6 (31.2-44.7)			37.8 (31.9–44.7)	0.017
CD4 cell count at ART initiation, cells/ μ L			139.0 (67.0-			138.0 (58.0-			139.0 (64.0-	0.244
			208.1)			217.8)			210.0)	
CD4 cell count available at disengagement	1,826	21.5		772	31.4		2,598	23.7		
CD4 cell count at disengagement (<2 months prior to last visit			293.5 (175.0-			314.0 (136.0-			297.0 (166.0-	0.040
before disengagement), cells/μL			432.8)			495.2)			452.8)	
CD4 cell-count measurements from reengagement to ART restart	3,985	36.4		0	0.0		3 <mark>,</mark> 985	36.4		
available ^a										
CD4 cell count from reengagement to ART restart ^a , cells/ μ L			248.0 (126.0-			N/A			248.0 (126.0-	
			412.0)						412.0)	
Time from ART initiation to disengagement, months			12.9 (4.9–25.5)			10.8 (3.4–23.0)			12.5 (4.5–25.1)	< 0.001
Time from disengagement to reengagement, months			2.7 (2.1–5.0)			3.2 (2.2-7.1)			2.7 (2.1–5.4)	<0.(y
Restart of ART	8,156	95.9		2,131	86.6		10,287	93.9		Feedback).0>
ART restart at reengagement in care	7,003	82.4		2,021	82.2		9 , 024	82.3		
Time from disengagement to ART restart, months <u></u>			2.9 (2.2-6.0)			3.5 (2.2-9.6)			3.0 (2.2-6.6)	<0.001

RIAS CD4 cell count testing dilemma



- Little or no consultative-stakeholder opinion for these huge manufacturing changes
- Is use of POC LFA CD4 feasible in all clinics or is sample transport still needed
- How will we prevent AIDS deaths without this tool?



»How can DSD principles be used to deliver the AHD package?



Two scenarios:

Re-engagement with AHD from in-patient department Re-engagement with AHD from out-patient department/ primary health centre



Components to consider when designing the building blocks for DSD models for clients with AHD at re-engagement

- Identifying AHD
- Clinical package to screen, prevent and treat opportunistic infections (OIs) in patients with advanced HIV disease
- Rapid ART initiation and/or regimen switch
- Linkage in-patient department (IPD) outpatient department (OPD)/ Primary health care (PHC) for ongoing care
- Intensive follow up first 3 months
- Management of HVL





What are the opportunities for **decentralization** and **task sharing** for delivery of the advanced HIV disease package?

What policy changes are needed to enable this?



	Component 1: Identifying advanced HIV disease					
	Identifying clinical signs and symptoms	Performing CD4				
WHEN Service frequency	At initiation Each clinical visit At re-engagement Any time in the community					
WHERE Service location	Facility Out of facility					
• WHO • Service provider	Doctor Nurse Community cadre (including CATS, key population peer supporter, CARG member) Client					
WHAT Service package	Identification of red flags and danger signs and symptoms					

	Component 1: Identifying advanced HIV disease					
	Identifying clinical signs and symptoms	Performing CD4				
WHEN Service frequency	At initiation Each clinical visit At re-engagement Any time in the community	At time of HIV diagnosis Re-engaging in care after more than 3 months off ART If VL >1000 copies/ml Presenting clinically unwell on ART				
WHERE Service location	Facility Out of facility	Facility Out of facility				
WHO Service provider	Doctor Nurse Community cadre (including CATS, key population peer supporter, CARG member) Client	Laboratory technician/scientists Microscopist Nurse Primary counsellor				
WHAT Service package	Identification of red flags and danger signs and symptoms	CD4, where possible at POC				

	Component 2: Clinical package to screen and prevent AHD (WHEN)						
	TB LAM	XPERT MTB/RIF	Blood CrAG	Fluconazole pre-emptive treatment	CTX	TPT	
	Outpatient and inpatient settings: in adults, adolescents and children with HIV • With signs and symptoms of TB	Whenever presenting with TB symptoms	If CD4 <200 cells/mm ³	If blood CrAG is positive and LP CrAG (if feasible) is negative	WHO clinical Stages 2, 3 and 4 CD4 cell count <350 cells/mm ³	TB screening negative Assessment for TPT repeated every three years	
WHEN Service frequency	 With advanced HIV disease Who are seriously ill Irrespective of signs and symptoms of TB and with a CD4 cell count <200 cells/mm³ 	``` V		ed from nation time as HIV t			


	Component 2: Clinical package to screen and prevent AHD (WHERE)						
	TB LAM	XPERT MTB/RIF	Blood CrAG	Fluconazole pre-emptive treatment	CTX	TPT	
WHERE	POC at same site as CD4 testing (inpatient, outpatient, primary care, out-of-facility site where trained cadre present) where possible			Inpatient Outpatient Primary care site	Inpatient Outpatient Primary care site	Inpatient Outpatient Primary care site	
Service location	Cont to populat tosting site			Out-of- facility site where trained cadre present	Out-of- facility site where trained cadre present		

	Compor (WHO)	ent 2: Clini	cal package	e to screen	and p	revent AHD
	TB LAM	XPERT MTB/RIF	Blood CrAG	Fluconazole pre-emptive treatment	CTX	TPT
	Laboratory te	chnician/scientists		Doctor	Doctor	Doctor
WHO	Microscopist			Nurse	Nurse	Nurse
Service • provider	Nurse Primary couns	sellor				Primary counsellor for telehealth follow-up
+		/iewpoint]
		CrossMark	for the implementat in sub-Saharan Africa		/ disease	

Ndlovu Z et al Lancet HIV. 2020 Jul;/(/):e514-e520. doi: 10.1016/S2352-3018(20)30101-6.

XIAS

What about re-engagement at IPD? Linkage between district hospital and outpatient/PHC/community follow up





•

•

- Before implementing the model, an average of 55% of clients needing ART were confirmed to have initiated treatment following hospital admission.
 - After implementation, **OVE**
 - **90%** of clients had initiated ART within 28-days post-discharge
 - This model can be described using the building blocks approach



http://programme.aids2020.org/Abstract/Abstract/5558



Differentiated follow-up schedule (first 3 months after initiation/switch)

Follow-up in the first three months is differentiated into:

• Standard

• Intensive

Activity	Criteria for intensive follow-up
Clinical monitoring	Active OIs or AHD identified
Counselling	Mental health condition identified, drug or substance misuse, adolescents, pregnant or breastfeeding women, key populations
Viral load monitoring	Earlier VL at month three for pregnant and breastfeeding women Where available, use of POC VL for children, adolescents, pregnant and breastfeeding women
	Where POC not available, flag specimen as urgent on request form for children, adolescents, pregnant and breastfeeding women

XIAS

Key messages

- Still significant (at least one in four initiations) number of clients with AHD at initiation
- Duration of dis-engagement increases the risk of presenting with AHD. Are our tracking procedures having an impact?
- DSD principles can be applied to the design of service delivery models for clients with AHD at re-engagement